Prenetics Acquires ACT Genomics First M&A Deal since IPO Set to Expand Footprint in Cancer Genomics
Prenetics will be acquiring a majority stake in ACT Genomics Holdings Company Limited ("ACT") for an upfront consideration consisting of 19.9 million shares of Prenetics common stock and US$20 million cash Prenetics expects ACT to contribute revenues of approximately US$25-30 million in 2023 Position Prenetics solidly within the US$80+ billion global precision oncology market Professor Tony Mok, C...
read full article
